NCT00208221终止3 期
Comparison of a Higher Dose of Ramipril to the Addition of Telmisartan 80 mg+Ramipril 10 mg in Patients With Hypertension and Diabetes
Institut de Recherches Cliniques de Montreal1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2006年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Microalbuminuria
研究概览
简要总结
The purpose of this study is to determine if a dose of ramipril combined with a normal dose of telmisartan 80 mg will be more effective than ramipril 20 mg in reducing microalbuminuria in hypertensive patients with diabetes.
详细描述
The purpose of this study is to determine the effects of ramipril 10 mg and telmisartan 80 mg versus ramipril 20 mg in patients with diabetes type II, hypertension and microalbuminuria (Urinary-albuminuria creatinine ratio of 2.0 to 25 mg/mmol) on
- Microalbuminuria
- Blood pressure (systolic, diastolic and ABPM), Renin-angiotensin system, Catecholamines, Oxydative stress
- Comparison at 4, 8 and 12 weeks with addition of hydrochlorothiazide 12.5 mg if BP over 130/80 mmHg
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female over the age of 18 years
- •Diastolic blood pressure (DBP) greater tha 80 mmHg and less than 104 mmHg
- •Type II diabetes on diet or oral hypoglycemic agents with a hemoglobin A1C (HbA1C) less than 0.080
- •UA ratio albumin:creatinine 2.0 to 25 mg/mmol
排除标准
- •DBP > 104 mmhg
- •Woman not surgically sterile or menopausal.
- •Premenopausal women whoo are not surgically sterile or who are not practicing acceptable means of birth control and do not agree to submit to periodic pregnancy tests.
- •Known or secondary forms of hypertension.
- •Intolerance to angiotensin (AT) 1 receptor blockers or angiotensin-converting enzyme (ACE) inhibitors.
- •Hepatic or renal dysfunction. Creatinine > 150 umol or enzymes greater than 2 times upper limit of normal.
- •Hemodynamically significant renal artery stenosis, renal artery stenosis on a solitary kidney, post-renal transplant or with only one kidney.
- •Uncorrected volume depletion.
- •Biliary obstructive disorders.
- •NYHA functional class congestive heart failure (CHF) III-IV.
- •Coronary heart disease needing pharmacological therapy.
- •Stroke within the preceding six months.
- •Percutaneous transluminal coronary angioplasty (PTCA) within the preceding three months.
- •History of angioedema.
- •Sustained ventricular tachycardia, atrial fibrillation, or other clinically relevant cardiac arrhythmias as determined by the clinical investigator.
- •Second or third degree AV block, left bundle branch block or any clinically relevant conduction abnormality as determined by the clinical investigator.
- •Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve.
- •Administration of digoxin.
- •Patients with a fasting glucose greater than 7.0
- •History of drug or alcohol dependency.
- •Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin II antagonists, alpha-blockers, beta-blockers, calcium channel antagonists, direct vasodilators that cannot be stopped for the trial.
- •Administration of other non-antihypertensive medications known to affect blood pressure (e.g. oral corticosteroids, monoamine oxidase [MAO] inhibitors, nitrates) at any time during the trial.
- •Chronic use of salt substitutes containing potassium chloride; potassium supplements; extreme dietary restrictions.
- •Uncorrected sodium depletion as defined by a serum sodium level less than 135 mEq/L.
- •Clinically significant hyperkalemia as defined by serum potassium level greater than 5.2 mEq/L. Clinically significant hypokalemia as defined by serum potassium level less than 3.0 mEq/L.
- •Patients receiving any investigational therapy within one month of signing the informed consent form.
- •Known hypersensitivity to any component of telmisartan, ramipril or hydrochlorothiazide.
- •Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of trial medication.
- •Blood donation in the preceding 1 month.
结局指标
主要结局
Microalbuminuria
次要结局
- Plasma renin
- plasma angiotensin
- plasma aldosterone
- plasma catecholamines
- oxydative stress
- diastolic blood pressure
- systolic blood pressure
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular LymphomaFollicular LymphomaNCT01393756The Lymphoma Academic Research Organisation80
已完成
不适用
Bioequivalency Study of Ramipril 10 mg Capsules Under Fed ConditionsHypertensionNCT00702260Roxane Laboratories39
Unknown
4 期
Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic NephropathyDiabetes Type 2Vascular DiseaseDiabetic NephropathyNCT01743014AHEPA University Hospital60
Unknown
4 期
Safety and Efficacy of Ramipril in the Treatment of Essential HypertensionEssential HypertensionNCT00366119Pacific Pharmaceuticals86
Unknown
2 期
Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to MonotherapyHypertensionNCT02791958Ferrer Internacional S.A.528